Recognition of the global importance and the rising prevalence of chronic respiratory diseases, such as cystic fibrosis (CF), and the absence of effective therapeutic treatments, has recently prompted a great deal of research efforts into the development of new oligonucleotide (ON) therapeutics, addressing the underlying pathology of lung diseases [1], [2] Among molecular targets, the nuclear factor-κB (NF-κB) transcriptionally regulates the expression of several inflammatory mediators, such as cytokines and chemokines (e.g., IL-6 and IL-8) [3]. Here, NFKB1 is linked to cystic fibrosis.